Six unrelated families with genetically determined structural variants of apo A-I were found in the course of an electrophoretic screening program for apo A-I variants in dried blood samples of newborns. The following structural variations were identified by the combined use of HPLC, time-of-flight secondary ion mass spectrometry (TOF-SIMS), and automated gas phase sequencing: Pro3 --Arg (1X), Pro4 Arg (1X), and Pro165--Arg (4X). All variant carriers were heterozygous for their mutant of apo A-I.
Introduction
Apo A-I, in its mature form a polypeptide of 243 amino acids of known sequence (1, 2) , is the major protein component of plasma HDL. It is secreted as proapo A-I by hepatic and intestinal cells (3, 4) with an aminoterminal hexapeptide that is cleaved extracellularly by a propeptidase (5, 6) . Neither this July 1989. proapo A-I-propeptidase nor its recognition site in proapo A-I have been identified to date. Analysis of synthetic peptides (7) (8) (9) (10) and structural variants of apo A-I (1 1, 12) revealed that amino acid residues that are located between positions 99 and 186 and are supposed to form repetitive amphipathic alphahelices ( 13) mediate biological functions ofapo A-I: solubilization of lipids in an aqueous environment (14) , and activation of the cholesterol esterifying enzyme lecithin:cholesterol acyltransferase (15) . In vitro HDL as well as apo A-I containing proteoliposomes have been demonstrated to bind specifically to various cells and promote cholesterol efflux (16) (17) (18) (19) . Because of its in vitro functions apo A-I is supposed to be a key protein in reverse cholesterol transport (20) , by which excess cholesterol is transported from peripheral cells to the liver for final deposition into the biliary tract. Results from epidemiological studies and clinical data have supported this hypothesis; decreased levels of HDL cholesterol (21) as well as low levels (22) or absence of apo A-I (23, 24) have been found associated with premature atherosclerosis. Previously, genetically determined structural variants of apo A-I have been identified by electrophoretic screening. They were informative to characterize structure-function relationships and to better understand the role of apo A-I in the pathomechanism leading to dyslipidemia or atherosclerosis (1 1, 12, 25-29) .
Recently our laboratory reported a simple and rapid method for the structural analysis of mutant apolipoproteins. This method combines the isolation of variant isoproteins from plasma or serum by isoelectric focusing in immobilized pH gradients, separation of proteolytic peptides by reversed phase HPLC and molecular weight determination by time-offlight secondary ion mass spectrometry 28) .' This technique allows the precise identification of amino acid substitutions predicted from mass analysis without sequencing the whole variant protein. Using this procedure we analyzed the amino acid substitutions in the structural variants of apo A-I, which were found in 16 families by an electrophoretic mutation screening of 32,000 newborns. Here we report three different mutants assessed in six unrelated families in which proline residues were substituted by arginine. Because proline has great impact on the folding of proteins (30) , its substitution could alter the secondary and tertiary structure of the protein.
Conformational changes should influence structure-function relationships and thus could have impact on the metabolism of apo A-I. We further studied the in vivo effects of the variant protein by comparing the relative concentrations of the normal and the variant apo A-I isoproteins in individuals heterozygous for the variants.
Methods
Subjects. 6 unrelated families with genetic variants of apo A-I reported here were found together with 10 other variants in a mutation screening program of 32,000 dried blood samples of newborns (von Eckardstein, A., T. Sgraja, and K. Altland, unpublished observations). For the structural analysis of the mutant proteins the parental carriers of the variants, who were determined in the course of the screening, were asked for a donation of 100 ml of blood. Family studies were performed in three families in which an apo A-I(Pro]65 -. Arg) mutation was vertically transmitted. For this purpose, depending on the age of the investigated subjects, 10-50 ml EDTA blood were taken. A fourth family (Jo), which was affected by the same variation, did not agree to participate in a family study. Control populations for comparing plasma concentrations of lipids and apo were taken from the Prospective Cardiovascular Munster (PROCAM) study (31 Preparation of isoproteins of apo A-I. Apo HDL isolated from 20 ml plasma by sequential ultracentrifugation (36) and delipidation (37) were solubilized in a buffer containing 5 mM sodium dihydrogen phosphate, 1% decylsulfate (wt/wt), 100 mM DTT, and 6 M urea (pH 8.0). Isoproteins of apo A-I were separated by isoelectric focusing in gels with immobilized pH gradients (Pharmacia-LKB, Bromma, Sweden). 5-mm-thick gels with pH gradients ranging from 5 to 6 were casted following the producer's recommendations (38) ; however, using only one-third of the recommended concentration of immobilines (33) . The washed gels were rehydrated with 6 M urea and 15% glycerol (wt/vol). Separation of solubilized apo HDL was performed overnight at 2,000 V, 15 mA, and S W and for 4 more h at 3,000 V. The apo A-I isoforms were seen in the unstained gels as opalescent lines. Gel strips containing the variant isoproteins were cut out of the gel without prior staining. After electroelution for 24 h in a 0.05 M Tris HCl buffer (pH 9.0) the proteins were dialyzed against 0.01 M ammonium hydrogen carbonate (pH 7.8) for 24 h. Subsequent lyophilization and solubilization in 0.01 M ammonium hydrogen carbonate (pH 7.8) was followed by purification by reversed phase HPLC. A C 18 column with a length of 250 mm and a diameter of 4 mm (E. Merck, Darmstadt, FRG) was run with a gradient from 0% acetonitrile in 0.1% trifluoroacetic acid (eluent A) to 100% acetonitrile without trifluoroacetic acid (eluent B). The flow rate was I ml/min. The acetonitrile content of the gradient was increased to 30% within the first 10 min, 45% within the next 15 min, and 100% within the last 10 min.
Proteolytic digestion ofisoproteins. Lyophilized apo A-I isoproteins were solubilized in 0.01 M ammonium hydrogen carbonate (pH 7.8) and digested with trypsin (activity, 212 U/mg protein; Cooper Biomedical, Wiesbaden, FRG) at a ratio of 40:1 (wt/wt). The solution was incubated for 24 h at 37°C.
HPLC separation ofproteolytic peptides. 500 ,ug of the proteolytic digest were separated by reversed phase HPLC using the LiChrospher CH 18 HPLC column, the eluents, and the flow described above. The acetonitrile content of the gradient was increased to 40% within 55 min and to 100% in the following 2 min. A peak detector monitoring at 215 nm and a fraction collector (Pharmacia-LKB) were used to collect the peptides separately.
Characterization ofproteolytic peptides by mass spectrometry and sequence analysis. HPLC fractions whose retention times or relative peak areas were different from those of normal apo A-I were analyzed by TOF-SIMS (28) . Mass differences between peptides of normal apo A-I that were lost from the chromatogram, and peptides of variant apo A-I that were newly generated, were used to calculate possible amino acid substitutions. Predicted amino acid substitutions were confirmed by sequence analysis of the affected tryptic peptides. Sequence analysis was performed by automated gas phase protein sequencing (Applied Biosystems, Foster City, CA).
Results
Description ofthe investigated subjects. Six families with three different electrophoretic variants of apo A-I were found by a mutation screening program of newborns (n = 32,000; von Eckardstein, A., T. Sgraja, and K. Altland, unpublished observations). The apo A-I mutants were identified by isoelectric focusing by the presence of additional protein bands with distinct charge differences in comparison with normal apo A-I. It was proven by two-dimensional immunoelectrophoresis and by immunoblotting (data not shown) that the additional bands represented apo A-I. All investigated families were unrelated. The affected subjects were heterozygous for the variant apo A-I. Pedigrees of three families with an apo A-I(Pro165 -o Arg) variant are presented in Fig. 1 . Vertical transmission of the variant apo A-I was observed in all families.
Lipid values and apolipoprotein concentrations of all investigated subjects are given in Table I . Carriers of the apo A-I(Pro165 --Arg) variant exhibited significantly lower levels of HDL cholesterol (37±9 vs. 64±18 mg/dl, P < 0.001, twotailed t test) and apo A-I (109±16 vs. 176±41 mg/dl, P < 0.001, two-tailed t test) than the unaffected members (see Table II ). In families Ke (Fig. 1 B) and Ler ( Fig. 1 C) the variant carriers exhibited apo A-I concentrations below the fifth percentile of PROCAM controls. In family Leh (Fig. 1 A (Fig. 2) . Apo A-I was undetectable in apo LDL of all investigated subjects. In plasma, apo VLDL, apo HDL, and LPDS of subjects Wi and Ler the peaks of normal and variant apo A-I were equal in altitude. However, in variant carriers of families Ler, Leh, Ke, and Jo total plasma, apo VLDL, and apo HDL shared distinctly smaller peak areas for the variant isoform than for the normal isoform. However, in LPDS of these probands both isoforms were found in equal concentrations. To exclude the possibility that reduced peak areas were due to changes in antigenicity of the variant apo A-I, apo A-I isoforms from all fractions were separated by double one-dimensional electrophoresis and analyzed by scanning densitometry of the stained bands in triplicate gels. Results of this analysis were confirmatory for those obtained with two-dimensional immunoelectrophoresis. In subjects M. Wi and M. Gu the ratios of variant to normal apo A-I were near one. In variant carriers of families Ler, Leh, Ke, and Jo the ratios of normal to variant apo A-I in total plasma, apo VLDL, or apo HDL were found near two, and they were found close to one in LPDS.
By isoelectric focusing and subsequent immunoblotting of total plasma from subject M. Gu the concentration of the variant proapo A-I appeared markedly higher than that of the normal proapo A-I. Relative concentrations of proapo A-I were found to be normal in all other mutants. This observation was validated by quantitative analysis. Fig. 3 shows the electrophoretic pattern and the corresponding densitogram of apo A-I isoforms separated from apo HDL of subject M. Gu. Concentrations of normal and variant mature apo A-I were similar. The ratio of variant to normal proapo A-I was approximately three. In heterozygous carriers of other variants this ratio was one. In apo VLDL and in LPDS proapo A-I concentrations were too low for reliable analysis.
Analysis of structural variations in the apo A-I variants. Fig. 4 shows the HPLC chromatogram of tryptic peptides and their location in the amino acid sequence of normal human apo A-I (2). Peptides were identified by the combination of molecular weight determination with TOF-SIMS and automated gas phase sequence analysis. HPLC-chromatograms obtained by separating the proteolytic peptides of variant proteins were compared with those from normal apo A-I. Fig. 5 shows the chromatogram of the variant apo A-I from a variant carrier of family Leh. The fraction containing peptide T26 was markedly reduced and two fractions containing peptides T26", and T26,2 were newly generated. The molecular masses of these peptides were 596 (T26X1) and 781 D (T26X2), respectively (Fig. 6) . Assuming a single base change as the underlying defect, the replacement ofproline at position 165 by arginine is the only amino acid substitution within T26, which can explain both an electrophoretic charge difference of + 1 and the formation of two tryptic peptides with molecular masses of 596 and 781 D. T26X, consisted of Thr-His-Leu-Ala-Arg as shown by sequence analysis. In normal apo A-I the unique sequence Thr-His-Leu-Ala (residues 160 --164) is followed by a proline residue in position 165 (Fig. 7 a) (Fig. 7 b) cholesterol compared with unaffected family members as well as normal controls from the PROCAM study. 9 of 12 cases represented apo A-I concentrations below the fifth percentiles of sex-and age-matched controls. Normal apo A-I values were only found in the variant carriers belonging to generation II of family Leh. This might be related to an HDL cholesterol-increasing gene effect transmitted by the mother of these subjects. In summary, besides apo A-I(Milano), in which an arginine in position 173 is replaced by a cysteine (25, 39) , apo A-I(Pro165 --Arg) is the second case of an apo A-I variant, which has been shown to quantitatively affect the plasma concentrations of apo A-I and HDL cholesterol.
In general, the concentration of the variant protein was found diminished in total plasma, isolated VLDL, and isolated HDL, but not in LPDS of affected subjects. Detailed electrophoretic and immunochemical analysis showed a reduction of the mutant isoform in the plasma ofthese probands to -50% of the normal isoform's concentration. It thus appears that the observed apo A-I deficiency in carriers of apo A-I(Pro165 -o Arg) can largely be attributed to the diminished concentration of this variant. At present it remains unclear whether the observed reduction ofplasma apo A-I associated with this variant is related to alterations in its anabolism or its catabolism. The Pro165 --Arg substitution affects a putative beta turn between two neighboring helices of the alpha-helical domain (13) . In a similar variant, apo A-I(Pro143 --Arg), such a localization has been proposed to be responsible for the diminished lipid binding and lecithin:cholesterol acyltransferase cofactor activity of this variant (12) . Application of the Chou-Fasman algorithm (40-42) reveals that the Pro165 -* Arg substitution lowers the beta turn probability of the tetrapeptide Ala-Pro-Tyr-Ser (residues 164 --167). Therefore it is reasonable to speculate that this substitution may result in an altered conformation of the protein's alpha-helical domain. Although Chou and Fasman defined the cutoff for the prediction of a beta turn at 0.5 X l0-4, the dramatic lowering ofthe beta turn probability by a factor of almost 3, from 2.18 X l0-4 to 0.77 X l0-4, to a value near the cutoff suggests that an effect of this mutation on the stability of the protein's conformation is possible.
Apo A-I(Pro3 -> Arg) and apo A-I(Pro4 --Arg). The relative concentration of the variant proapo A-I was shown to be distinctly increased compared with normal proapo A-I in an individual heterozygous for apo A-I(Pro3 -. Arg), whereas in a person heterozygous for apo A-I(Pro4 -* Arg) this phenomenon was not observed. In a further subject heterozygous for apo A-I(Pro3 -* His) (26) the variant proform was also found overrepresented (unpublished observations). A relative enrichment of the proapo A-I in plasma is characteristic for Tangier disease, a heritable disorder of lipoprotein metabolism with extremely low plasma concentrations of HDL, apo A-I, and apo A-II (43, 44) . In this condition the overrepresentation of proapo A-I is probably due to hypercatabolism of HDL and apo A-I (45, 46). In proband M. Gu heterozygous for apo A-I(Pro3 -Arg) the products of both the normal and the mutant allele were nearly equal in plasma concentration. Total plasma concentrations of apo A-I and HDL cholesterol in M.
Gu were not reduced. Therefore accelerated catabolism probably does not account for the enrichment of proapo A-I in this subject. Rather normal apo A-I consists of an alpha helix. Subsequent proline residues at positions 3 or 4 of mature apo A-I can form a beta turn that may fulfill the structural requirement for the formation of a recognition site for the proapo A-I-propeptidase. As proline residues mostly occupy the second position in a tetrapeptide forming a beta turn, in the case of proapo A-I the two neighboring proline residues in positions 3 and 4 give rise to two possible formations of a beta turn (Table III) . Application of the Chou-Fasman algorithm (40) (41) (42) reveals that the beta turn probability is higher for the tetrapeptide Pro-Pro-Gln-Ser (residues 3 --6 of apo A-I) than for the tetrapeptide Glu-ProPro-Gln (residues 2 -* 5). However, replacement of proline in position 3 by arginine or histidine, but not of proline in position 4 by arginine apparently interferes with the formation of a beta turn at the aminoterminal end of apo A-I (Table III) . For this reason, and because in several species including pig (47), dog (48) , rat (49) , rabbit (50) , and chicken (51, 52 ) only one of the two prolines (position 3) is present in an otherwise highly conserved region, it appears more likely that a beta turn is formed by the proline immediately after the glutamic acid residue. Overrepresentation ofproline substitutions in apo A-I variants. The present study and two previous reports (12, 26) led to the identification of five apo A-I mutants involving proline residues. In each case the proline in the wild type sequence was replaced by another amino acid; four times proline was substituted by arginine and once it was changed to histidine. In apo A-I no switch of any amino acid to proline has been reported to date, although based on codon frequencies in the apo A-I gene one should expect as many mutations in the reverse direction. Barker proline substitutions in apo A-I, a more detailed analysis of point mutations occurring in certain codons requires screening techniques, which are also sensitive for electrically neutral amino acid substitutions.
Neither the crystallographic structure of apo A-I nor the functional characteristics of the propeptidase are known today. However, as shown in this study, the combined use of secondary structure predictions, interspecies comparisons, and experimental data derived from naturally occurring structural variants may yield information on structure-function requirements in the processing of apo A-I. At present it is not known whether the apo abnormalities reported here put their carriers 
